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Summary
Background: The PINK1-Parkin pathway is known to play
important roles in regulating mitochondria dynamics, motility,
and quality control. Activation of this pathway can be triggered
by a variety of cellular stress signals that cause mitochondrial
damage. How this pathway senses different levels of mito-
chondrial damage and mediates cell fate decisions accord-
ingly is incompletely understood.
Results: Here, we present evidence that PINK1-Parkin has
both cytoprotective and proapoptotic functions. PINK1-Parkin
operates as a molecular switch to dictate cell fate decisions in
response to different cellular stressors. Cells exposed to se-
vere and irreparable mitochondrial damage agents such as
valinomycin can undergo PINK1-Parkin-dependent apoptosis.
The proapoptotic response elicited by valinomycin is associ-
ated with the degradation of Mcl-1. PINK1 directly phosphor-
ylates Parkin at Ser65 of its Ubl domain and triggers activation
of its E3 ligase activity through an autocatalytic mechanism
that amplifies its E3 ligase activity toward Mcl-1.
Conclusions: Autocatalytic activation of Parkin bolsters its
accumulation on mitochondria and apoptotic response to va-
linomycin. Our results suggest that PINK1-Parkin constitutes
a damage-gated molecular switch that governs cellular-
context-specific cell fate decisions in response to variable
stress stimuli.
Introduction
Mutations in PINK1 and Parkin are associated with early-onset
familial autosomal recessive Parkinson’s disease (PD) [1, 2].
Although the exact molecular mechanism that causes PD is
not clearly understood, genetic studies in model organisms
coupled with mechanistic studies in mammalian cells suggest
that PINK1 acts upstream of Parkin to regulate mitochondrial
integrity, dynamics, and motility [3–5].
The level of PINK1 is low in unperturbed mitochondria due
to proteolytic degradation of PINK1 by the protease ParL
and subsequent retrotranslocation into the cytosol for protea-
somal degradation [6]. Upon the loss of mitochondrial mem-
brane potential by decouplers, such as cyanide, the import
and degradation of PINK1 are blocked, allowing it to accumu-
late on the outer mitochondrial membrane [7–9]. Increased*Correspondence: xuedong.liu@colorado.eduexpression and activity of PINK1 lead to phosphorylation of
mitofusin 2 [10], Parkin [9, 11], Miro [12], and other substrates.
Elevated PINK1 activity promotes translocation of Parkin
from the cytosol to the mitochondria. In accordance with the
significance of Parkin mitochondrial recruitment, many pa-
tient-derived Parkin mutants are defective in mitochondrial
translocation [13, 14]. Parkin is a member of the RING-IBR-
RING (RBR) family of ubiquitin E3 ligaseswith a conserved cat-
alytic cysteine residue analogous to the HECT domain E3s
[15]. The autoubiquitination activity of Parkin is abolished if
this residue is mutated [16, 17]. A diverse set of protein sub-
strates have been shown be ubiquitinated by Parkin [2],
including several proteins localized in the mitochondrial outer
membrane, such as Mfn1 and Mfn2 [10, 18, 19], Drp1 [20],
voltage-dependent anion channel 1 (VDAC1) [21], and Miro
[12]. Ubiquitination and degradation of these proteins is linked
to mitochondrial fission during mitophagy or mitochondrial
motility. Proteomics studies revealed that Parkin may directly
or indirectly regulate ubiquitination of more than 100 mito-
chondrial proteins upon mitochondrial depolarization [22].
Despite these current insights, there are still many
outstanding questions that remain to be answered. First, the
mechanism by which PINK1 mediates Parkin mitochondrial
translocation is still incompletely understood. Second, it re-
mains to be determined how the E3 ligase activity of Parkin
is regulated. Biochemical and structure studies revealed that
Parkin exists in an autoinhibited conformation due to an inter-
action between the N-terminal ubiquitin-like (Ubl) domain, the
repressor element (REP), and the RING1 domain [23]. These
observations raise an interesting question about the potential
mechanisms that can allosterically activate Parkin in vitro and
in vivo. Finally, the diversity of Parkin substrates begs the
question whether there is selective ubiquitination of these
substrates and whether ubiquitination of these substrates
contribute to cell fate decisions in response to distinct cellular
stress stimuli.
The PINK1-Parkin pathway has also been shown to have
cytoprotective activity under various stress conditions [2, 5].
There appears to be distinct Parkin-dependent pathways for
preventing cell death depending on the severity of mitochon-
drial damage and the nature of stress signals. Reactive oxygen
species (ROS) can induce PINK1-Parkin-dependent repairing
damaged mitochondria through the mitochondria-derived
vesicle trafficking pathway [24]. Upregulation of Parkin-depen-
dent NF-kB signaling has a prosurvival role under moderate
stress [25]. Mitophagy is the best characterized PINK1-Par-
kin-dependent pathway for removal of damagedmitochondria
[4]. Collectively, these results suggest that the PINK1-Parkin
nexus can mount different cellular responses depending on
the levels of cell stress signals.
Here, we investigated mechanisms by which PINK1-Parkin
regulates cell survival. We discovered that beyond its well-
recognized cytoprotective function, PINK1-Parkin is also
required for valinomycin-induced apoptosis. Mechanistically,
the proapoptotic function of PINK1-Parkin in response to se-
vere apoptotic signal is associated with ubiquitination of the
antiapoptotic protein Mcl-1 and activation of the caspase
cascade. We reconstituted Parkin-dependent ubiquitination
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ulates the Parkin E3 ligase activity through phosphorylation of
Ser65 of Parkin. This phosphorylation event sets off autocata-
lytic activation of Parkin. Finally, our study showed that ubiqui-
tin is also a substrate for PINK1 and phosphorylated ubiquitin
promotes Parkin mitochondrial targeting and afford additional
elevation of Parkin activity. Our results reveal a new function
of the PINK1-Parkin pathway in cell fate decisions and a Parkin
activation cascade in response to diverse stress stimuli.
Results
Parkin-Dependent Mitophagy and Apoptotic Cellular
Responses in Response to Mitochondrial Depolarization
It is well established that the PINK1-Parkin pathway is involved
in elimination of depolarized mitochondria by mitophagy [26].
As expected, HeLa cells stably expressing fluorescence pro-
tein tagged wild-type Parkin, but not mutant Parkin T240R
(seen in Parkinson’s patients), undergo mitophagy in the pres-
ence of the mitochondrial uncoupler protonophore carbonyl
cyanide m-chlorophenyl hydrazone (CCCP) (Figure 1A). The
mitophagic response can be demonstrated by the increased
colocalization of Parkin and LC3 with the mitochondria marker
RFP-Smac-mts (RFP-Smac)—a fusion of the mitochondrial
targeting sequence of Smac with RFP (Figures S1A and S1
and Movies S1 and S2 available online). Under these condi-
tions, no significant apoptosis is seen in either cell line based
on RFP-Smac release (Figure 1B).
To further probe specificity of Parkin-induced mitophagy
in response to mitochondrial depolarization, we tested mito-
phagic responses to a panel of mitochondrial damaging
agents, including rotenone, dinitrophenol, and valinomycin.
Surprisingly, we found only valinomycin, a potassium iono-
phore known to collapse the potassium gradient across the
mitochondrial inner membrane and depolarize mitochondria,
induces rapid cellular apoptosis in HeLa cells expressing
wild-type Parkin, but not Parkin T240R mutant (Figures 1C
and 1D and Movie S3). Valinomycin resistance is not due to
the expression of the Parkin mutant since wild-type HeLa
cells display identical apoptosis phenotype upon valinomycin
treatment (data not shown). Valinomycin-induced cell death
can be suppressed by treatment with the caspase inhibitor
Z-VAD-FMK, which is consistent with cell death by apoptosis
(Figures S1G and S1H). Both CCCP and valinomycin induce
rapid Venus-Parkin accumulation on mitochondria with similar
kinetics (Figures S1C–S1F). However, despite similar effects
on Parkin mitochondrial accumulation, cells exposed to these
two depolarizing agents adopt different cell fates.
PINK1 Is Required for Valinomycin-Induced
Parkin-Dependent Apoptosis
Because Parkin-dependent mitophagy requires PINK1 stabili-
zation and accumulation on mitochondria [7, 9, 13, 21], we
investigated whether PINK1 is also required for Parkin-dep-
endent apoptosis in response to valinomycin via small inter-
fering RNA (siRNA)-mediated silencing of PINK1. Similar to
what we observed for CCCP, valinomycin stabilized PINK1
expression (Figure 1F). As expected, PINK1 knockdown blocks
Venus-Parkin accumulation on mitochondria and stabilization
of PINK1 (Figures 1E and 1F). The levels of apoptosis are signif-
icantly reduced inPINK1knockdowncells (Figures1E–1G). This
result indicates that the PINK1-Parkin pathway is involved in
both mitophagy and apoptosis in response to the two different
stimuli.Valinomycin Specifically Suppresses the Expression of
Antiapoptotic Protein Mcl-1 and Activates Initiator
Caspase-8 and Caspase-9
To address the mechanism of valinomycin-induced apoptosis,
we initially assessed the expression of antiapoptotic proteins
and the activation status of several apoptotic hallmark proteins
in Parkin wild-type and Parkin T240R mutant HeLa cells (Fig-
ure 2A). Expression of Parkin T240R is higher than that of
wild-type Parkin, which may be a result of their differential sta-
bility in cells.However, thisdifference isunlikely tobe important
for interpreting the experimental results since Parkin T240R is
effectively null in valinomycin-induced apoptotic responses
and serves a better control to demonstrate the specificity of
PINK1-andParkin-dependentcellular responses. Interestingly,
in cells expressing wild-type Parkin, valinomycin treatment
slightly elevated PINK1 expression at 2 hr, after which levels
declined and suppressed. In contrast, valinomycin strongly
induced expression of PINK1 in HeLa cells expressing Parkin
T240R mutant (Figure 2A, top panel). The pattern of PINK1
induction in the absence of functional Parkin in HeLa cells is
reminiscent to CCCP treatment described previously [26].
Among the three well-characterized Bcl2 proteins, only Mcl-1
is significantly downregulated by valinomycin treatment in a
Parkin-dependent manner. No changes in Bcl-xL or Bcl2 were
observed. Valinomycin treatment causes activation of initiator
caspase-8 and caspase-9 within 4 hr in HeLa cells expressing
wild-type Parkin, but not in cells expressing mutant Parkin
(Figure 2A). In agreement with strong apoptotic activation by
valinomycin, effector caspase-3, caspase-7, and PARP are
cleaved in a Parkin-dependent manner (Figure 2A). To deter-
minewhether suppression ofMcl-1 is due to Parkin-dependent
ubiquitin-mediated degradation, we treated HeLa cells with or
without Parkin expression with valinomycin in the presence or
absence of the proteasome inhibitor MG132. High-molecular-
weightMcl-1 only presents in cells expressingParkin andaccu-
mulates in the presence of MG132 (Figure 2B, lane 8). This
finding suggests that Mcl-1 is most likely ubiquitinated by Par-
kinupon treatmentwith valinomycin.Activation of apoptosisby
valinomycin is associated with suppression of Mcl-1 and acti-
vation of the intrinsic and extrinsic apoptotic initiator caspases.
If Mcl-1 suppression is linked to differences in cell fate
upon exposure to CCCP and valinomycin, we would expect
that CCCP should not cause significant Mcl-1 degradation.
Immunoblotting analysis revealed that CCCP only causes a
slight drop in Mcl-1 and remains stabilized after 6 hr, as
opposed to the steady decline of Mcl-1 in response to valino-
mycin (Figures 2C and 2D). Conversely, if Mcl-1 level is a key
determinant of cell fate decision, reduction of Mcl-1 should
be sufficient to alter the CCCP response. To test this hypothe-
sis, we knocked down expression of Mcl-1 by small hairpin
RNA (shRNA; Figure 2E). As shown in Figure 2F, HeLa cells
with lower endogenous Mcl-1 undergo apoptosis in response
to CCCP. These data suggest that Parkin catalyzes selective
degradation of specific substrates in response to specific
stimuli. Suppression of Mcl-1 by Parkin is critical for differen-
tial cell fate decisions in response to CCCP and valinomycin.
Valinomycin Induces PINK1- and Parkin-Dependent
Apoptotic Response in MEFs
To determine whether the endogenous PINK1 or Parkin is
required for valinomycin-induced apoptosis in another cell
system, we first investigated the response to valinomycin in
mouse embryonic fibroblasts (MEFs) derived from the parental
and PINK1-knockout mice, as well as in MEFs from
Figure 1. Valinomycin Triggers Parkin Mitochondrial Recruitment and Apoptosis in a PINK1- and Parkin-Dependent Manner
(A–D) HeLa cells expressing RFP-Smac-mts and either Venus-Parkin-WT or Venus-Parkin-T240R were treated with 10 mM CCCP (A and B) or 10 mM
Valinomycin (C and D) in a 9 hr time course. Scale bars, 10 mm.
(A) CCCP induced mitochondrial recruitment of Parkin-WT, but not Parkin-T240R. Neither Parkin-WT nor Parkin-T240R triggered RFP-Smac release from
the mitochondria.
(B) Apoptotic cell death was quantified by counting of cells positive for RFP-Smac release. CCCP did not trigger significant RFP-Smac release in either
cell line.
(C) Valinomycin induced mitochondrial recruitment of Parkin-WT, but not Parkin-T240R.
(legend continued on next page)
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we monitored cell apoptotic responses during the time course
of valinomycin exposure by a caspase-3 activity sensor,
NucView 488 (Biotium). DEVD-NucView 488 caspase-3 sub-
strate is a cell-membrane-permeable fluorescence sensor.
Upon cleavage by active caspase-3, the DNA-binding dye is
released and migrates to the cell nucleus to stain the nucleus
bright green. The nuclei and their condensation states were
also scored independently by Hoechst 33258 fluorescence us-
ing an automated MetaXpress application module. As seen in
HeLa cells, parental wild-type MEFs are more prone to valino-
mycin-induced apoptosis than are PINK1- or Parkin-null MEFs
(Figures 3A and 3B). To further demonstrate that the endoge-
nous PINK1 has a proapoptotic role in valinomycin-induced
apoptotic response, we knocked down the expression of
PINK1 in wild-type MEFs using shRNA. A mammalian nontar-
geting (NT) shRNA was used as a control. Depletion of
PINK1 was confirmed by immunoblotting (Figure 3C). Treat-
ment with valinomycin-induced stronger apoptosis in control
MEFs (Figures 3C and 3D). Treatment with valinomycin also
suppressed Mcl-1 expression in the control MEFs (Figure 3E).
However, downregulation of Mcl-1 was partially abrogated in
PINK1 knockdown MEFs (Figure 3E). These results suggest
that valinomycin induces PINK1- and Parkin-dependent sup-
pression of Mcl-1 and apoptosis in MEFs.
We tested whether valinomycin sensitivity can be rescued in
PINK1- or Parkin-null MEFs by stably expressing the two
genes. The human versions of these geneswere used because
commercial antibodies against mouse Parkin are largely inef-
fective. Nevertheless, stable expression of human PINK1 and
Parkin fully restores the defects of valinomycin response in
MEFs that are deficient for either gene (Figures 3A and 3B).
Immunoblotting confirmed a similar pattern of regulation of
caspases and Bcl2 proteins as that seen in HeLa cells (Fig-
ure S2A), as well as Z-VAD-FMK sensitivity (Figures S2B and
S2C). These findings indicate that the PINK1-Parkin pathway
controls cell fate determination in response to valinomycin.
PINK1 Phosphorylates a Highly Conserved Ser65 Residue
in the Parkin Ubl Domain and Ubiquitin
To further probe the biochemical mechanisms by which PINK1
andParkin regulate cellular apoptosis,we investigatedhow the
PINK1 and Parkin activity controls Mcl-1 ubiquitination in vitro.
Our initial attempt was to use recombinant PINK1 to drive the
pathway. Despite intensive efforts, we were unable to detect
robust kinase activity of human PINK1. Previous studies by
Muqit and colleagues showed that an insect ortholog of
PINK1 (TcPINK1) from Tribolium castaneum is catalytically
active [28]. In agreement with the previous report, we find
that TcPINK1 can phosphorylate human Parkin1–108 and that
Ser65 is most likely the site targeted by TcPINK1 as no phos-
phorylation can be detected when Ser65 was mutated to Ala
(Figure 4A, lane 1 versus lane 2). Despite robust phosphoryla-
tion of recombinant human Parkin1–108 by TcPINK1 in vitro,
full-length human Parkin was reported to be a poor substrate(D) Quantitation of cell death by counting of cells positive for RFP-Smac relea
(E–G) HeLa cells expressing Venus-Parkin-WT were transfected with control
course. Apoptotic cell death was visualized by staining with Hoechst 33258,
labeling significantly increases in apoptotic cells as nuclei condense during
cell heath application module in MetaXpress software. Representative images
(E) PINK1-dependent apoptotic cell death was visualized by fluorescent micros
(F) Wild-type and PINK1 knockdown cells in response to valinomycin were im
(G) Apoptotic cell death was quantified by counting of cells positive for cells w
Error bars represent the SD. See also Figure S1 and Movies S1, S2, and S3.for TcPINK1 [11]. In light of the recent success with the full-
length rat Parkin (rParkin) protein in structural studies [23],
we tested whether recombinant rParkin may be a better sub-
strate for TcPINK1 because rParkin is well folded. As shown
in Figure 4B, rParkin is robustly phosphorylated by TcPINK1.
Mutation of catalytic Cys at 431 to Ser does not affect its
phosphorylation. However, mutation of Ser65 to Ala in the
Ubl domain of rParkin largely eliminates its phosphorylation
(Figure 4B, lanes 7–9). Since the Ubl domain of Parkin shares
significant sequence and structure homology with ubiquitin
and Ser65 is conserved and solvent exposed (Figures S3A–
S3C), we tested whether ubiquitin may also be a substrate for
PINK1. As seen with Parkin Ubl, TcPINK1 can phosphorylate
wild-type ubiquitin and this phosphorylation is significantly
reduced when Ser at 65 is mutated to Ala or Asp (Figure S4A),
suggesting that Ser65 is the primary phosphorylation site of
ubiquitin. These results indicate that PINK1 phosphorylates
Parkin and ubiquitin primarily at a single Ser residue (Ser65).
Mcl-1 Is a Substrate for Parkin E3 Ubiquitin Ligase
To demonstrate that Mcl-1 is a substrate for Parkin, we recon-
stituted Parkin-dependent Mcl-1 ubiquitination using highly
purified ubiquitin, Uba1(E1), UbcH7 (E2), rParkin, and Mcl-1
(Figure 4C). The mixture was incubated for 3 hr at room tem-
perature (Figure 4D). Polyubiquitination of Mcl-1 is more
robust with a ParkinW403A (Figure 4D, lane 7 versus lane 8), a
mutant that has been shown to inactivate the REP element
and to elevate its autoubiquitination activity [23]. A double
mutant with the substitution of catalytic Cys 431 to Ser has
no activity (Figure 4D, lane 9). Omission of any component
required in the ubiquitin transfer reaction abrogated poly-
ubiquitination of Mcl-1, suggesting this reaction is highly spe-
cific (Figure 4D, lanes 1–6). This finding indicates Mcl-1 is a
substrate for Parkin in vitro.
Activation of Parkin E3 Ubiquitin Ligase Activity by PINK1
through Phosphorylation of Parkin Ubl at Ser65
Given that Parkin Ser65 is phosphorylated by PINK1, we
analyzed the effects of Parkin phosphorylation on its autoubi-
quitination and Mcl-1 ubiquitination activity. As shown in Fig-
ure 4E, GST-rParkin is phosphorylated by PINK1, and this
phosphorylation is absent in GST-rParkinS65A, as detected
by a Parkin phospho-Ser65 antibody (Figure 4E, lane 2 versus
lane 3). Phosphorylation of Parkin greatly increases its auto-
and transubiquitination activity by the early appearance of
high-molecular-weight Parkin conjugates and ubiquitinated
Mcl-1 (Figure 4E, lanes 5 and 6 versus lanes 7 and 8). GST-
rParkinS65A is inactive in the presence or absence of PINK1
(Figure 4E, lanes 3 and 4 versus 9 and 10). Since PINK1
also phosphorylates ubiquitin at Ser65 (Figure S4A), we also
tested the effect of this phosphorylation on Parkin E3 ligase
activity. Ubiquitin was first incubated with PINK1 or kinase-
dead PINK1 for 2 hr to allow it to be phosphorylated. Phos-
phorylated ubiquitin and control ubiquitin were used as inputs
in the reconstituted Mcl-1 ubiquitination reaction by Parkinse in valinomycin-treated cells.
or PINK1 siRNA and were treated with 10 mM valinomycin in a 12 hr time
which enters all cells regardless cell health. The average intensity of DNA
apoptosis. Quantitation of cell death was performed using the automated
are shown. Scale bars, 10 mm.
copy. Cells were incubated with valinomycin for 1.5h prior to image capture.
munoblotted using an antibody for PINK1.
ith condensed chromatin at 12h. More than 500 cells were scored.
Figure 2. Valinomycin Induces Parkin-Dependent Suppression of Mcl-1 and Activation of Apoptotic Initiator Caspases
(A) HeLa cells expressing Parkin-WT or Parkin-T240R were subjected to 10 mM valinomycin in a 6 hr time course and were collected at 2 hr intervals.
Proapoptotic and antiapoptotic proteins were monitored by western blotting using antibodies for their respective proteins. Upon valinomycin treatment,
cells expressing Parkin-WT exhibited a depletion of Mcl-1 levels, activation of caspase-8 and caspase-9, and cleavage of caspase-3, caspase-7, and
PARP. The corresponding apoptotic response was not detected in cells expressing Parkin-T240R.
(B) HeLa cells with or without Parkin expression were treated with 10 mM valinomycin and/or 10 mMMG132 for 2.5 hr. The response was monitored by west-
ern blotting using an antibody for Mcl-1 and Parkin. Cells expressing Parkin degrade Mcl-1 when treated with valinomycin and accumulated Ub-Mcl-1 when
treated simultaneously with the proteasome inhibitor MG132.
(C) Effect of CCCP onMcl-1 levels. The indicated cell lines were treatedwith 10 mMCCCP in a 6 hr time course. EndogenousMcl-1 was blottedwith anti-Mcl-
1 with GAPDH as a loading control.
(D) Mcl-1 levels from (A) and (C) were plotted.
(E) Suppression of endogenousMcl-1 expression by shRNA. Stable knockdownHeLa cells expression Venus-Parkin andRFP-Smacwere obtained by infec-
tion with shRNA for Mcl-1.
(F) CCCP induces apoptosis in HeLa cells with reduced Mcl-1 expression. Apoptotic cell death was quantified by counting of cells positive for RFP-Smac
release. Error bars represent the SD.
See also Figure S2.
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Figure 3. Valinomycin-Induced Apoptosis Requires PINK1 and Parkin
(A and B) Wild-type MEFs, PINK1- or Parkin-null MEFs, or MEF nulls reconstituted with human PINK1 and Parkin were stained with NucView caspase-3
sensor and Hoechst 33258 and treated with 10 mM valinomycin for 12 hr. Apoptotic cell death was visualized with fluorescent microscopy (A) and was
quantified by measurement of the percentage of apoptotic nuclei (B). Scale bars, 10 mm.
(C) Wild-type MEFs were stably introduced with nontargeting or PINK1 shRNA and were treated with 10 mM valinomycin for 24 hr. PINK1 expression in
control and knockdown cells was measured by western blotting. Apoptosis was monitored by caspase-3 sensor and quantified.
(D) PINK1 knockdown attenuates valinomycin-induced apoptosis as determined by caspase-3 activation.
(E) PINK1 knockdown relieves the suppression of Mcl-1 level by valinomycin.
Error bars represent the SD.
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nated Mcl-1 showed up earlier than the control reaction
(Figure S4B, lanes 1–3 versus lanes 4–6) as well as the autou-
biquitinated Parkin bands. Consistent with the positive effect
of ubiquitin phosphorylation, phosphomimetic ubiquitinS65D
stimulates Parkin autoubiquitination more effectively than
does ubiquitinS65A with Ser65 phosphorylated rParkin or un-
phosphorylated rParkin (Figure S4C). These results indicate
that phosphorylation of Parkin by PINK1 contributes to its acti-
vation in vitro. The effect of ubiquitin Ser65 phosphorylation on
Parkin mitochondrial recruitment was tested by comparison of
HA-Ub and HA-UbS65A in HeLa cells expressing Venus-Parkin.
Expression of HA-UbS65A, but not HA-Ub, caused a significant
reduction in Parkin recruitment to mitochondria in response to
valinomycin treatment (Figures S4D and S4E). This result
points to a potential role for ubiquitin phosphorylation in Par-
kin recruitment to mitochondria.Phosphorylation of Parkin Ser65 Is Required for
Valinomycin-Induced Apoptotic Responses
To address the significance of Parkin Ser65 phosphorylation
in Parkin proapoptotic signaling in response to valinomycin,
we stably expressed mTurquoise-ParkinS65A in Parkin-null
MEFs and HeLa cells. The mitochondrial recruitment
behavior of mTurquoise-Parkin is identical to that of Venus-
Parkin (data not shown). Whereas valinomycin induces
wild-type Parkin mobility shift (Figure 5A), ParkinS65A is
largely unresponsive to valinomycin treatment. mTurquoise-
ParkinS65A is also defective in mitochondrial recruitment in
response to valinomycin (Figures 5B and 5C). MEFs express-
ing mTurquoise-ParkinS65A are resistant to valinomycin-
induced cell death (Figures 5B and 5C), suggesting that
phosphorylation of Parkin Ser65 is required for initiating Par-
kin recruitment to mitochondria and transducing apoptotic
signal.
Figure 4. Full-Length Parkin and Parkin Ubl Domain Are PINK1 Substrates and In Vitro Reconstitution of Mcl-1 Ubiquitination by Parkin
(A and B) In vitro kinase assay with [g-32P] ATP.
(A) UblWT-Parkin1–108 or UblS65A -Parkin1–108 as the substrate for TcPINK1WT. Ser65 in the Parkin Ubl domain is required for PINK1 phosphorylation.
(B) Phosphorylation of rParkinWT, rParkinC431S, or rParkinS65A by TcPINK1WT and kinase-dead TcPINK1D359A.
(C) Coomassie blue staining of proteins used in the in vitro ubiquitination reaction.
(D) In vitro ubiquitination assay was performed at 37C for 3 hr using 1 mM His6-Mcl-1 as the substrate and was monitored by western blotting using an
antibody for Mcl-1. rParkin-W403A exhibiting enhanced autoubiquitination and rParkinW403AC431S exhibiting no ligase activity were used as controls. rParkin
(0.7 mM) was used in ubiquitination reactions.
(legend continued on next page)
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and Mitochondrial Recruitment
Inefficient accumulation of ParkinS65A on mitochondria could
be due to its inability to associate with mitochondria or to
lack of catalytic activity to generate a positive feedback that
is required for rapid and efficient activation of Parkin. Since
Ser65 phosphorylated Parkin has robust autoubiquitination
activity, we reasoned that the defect of ParkinS65A inmitochon-
drial recruitment could be rescued by the presence of wild-
type Parkin in trans. We tested this hypothesis by expressing
Venus-Parkin and mTurquoise-ParkinS65A independently or
together in the same HeLa cells. As expected, Venus-Parkin
is recruited to mitochondria, whereas mTurquoise-ParkinS65A
is not, when expressed independently upon valinomycin treat-
ment (Figure 5D). In contrast, when both were coexpressed in
the same cell, we found that mTurquoise-ParkinS65A is effi-
ciently recruited and indistinguishable from Venus-Parkin at
2 hr (Figures 5E and 5F). Detailed kinetics analysis revealed
that there was an approximately 10 min delay in the early
phase of accumulation for mTurquoise-ParkinS65A and that
both approached similar levels at approximately 110 min (Fig-
ure 5G). This result suggests that catalytically active Parkin
converts ParkinS65A to thewild-type Parkin phenotype in terms
of mitochondrial recruitment.
One hypothesis that can explain the rescue of ParkinS65A
by wild-type Parkin is that Parkin activation is through an
autocatalytic mechanism. To test this hypothesis, we set up
an in vitro ubiquitination assay using a combination of wild-
type and mutant Parkin proteins (Figures 6A and 6B). An un-
tagged rParkinS65A was purified to mix with either GST-rParkin
or GST-rParkinS65A at 3:1 ratio for the ubiquitination reaction
after incubation with TcPINK1 to allow phosphorylation of
GST-rParkin to occur. With a 3-fold reduction of GST-rParkin,
the rate of Parkin autoubiquitination slowed down (Fig-
ure 6A, lanes 6–8 versus, Figure 4E, lanes 5 and 6). When non-
phosphorylatable untagged rParkinS65A was included in the re-
action, polyubiquitination of rParkinS65A occurred, judging by
the disappearance of the substrate (Figure 6A, top panel, lanes
3–5). No reaction was seen in the control with GST- rParkinS65A
with rParkinS65A (Figure 6A, lanes 9–11), suggesting that
neither protein has catalytic activity in the presence of
TcPINK1. With the Parkin pSer65 antibody, we can see that
the autoubiquitination rate of GST-rParkin increased dramati-
cally in the presence of rParkinS65A (Figure 6A, lanes 3–5 versus
lanes 6–8). This is unlikely to be due to the stimulation of GST-
rParkin phosphorylation by rParkinS65A since the overall phos-
phorylation of GST-rParkin stayed the same (Figure 6A, lanes
3–5). This result indicates that Parkin activation likely occurs
via an autocatalytic mechanism. PINK1 phosphorylation of
Parkin at Ser65 provides the initial spark for the nonlinear
amplification of Parkin activity.
Autocatalytic Activity, but not Mitochondrial Recruitment,
of Parkin Is Required for Parkin-Dependent Apoptotic
Response to Valinomycin
Previous studies have shown that mitochondrial expression
of linear ubiquitin chain promotes mitochondrial targeting of
ParkinC431S mutant that is defective in ubiquitin E3 ligase(E) Phosphorylation of Parkin Ser65 promotes Parkin auto- and transubiquitinat
TcPINK1 or kinase-dead TcPINK1 for 60 min prior to initiation of ubiquitinatio
phosphospecific antibody. Ubiquitin ligase activity wasmonitored bywestern b
reactions were terminated at the indicated times.
See also Figures S3 and S4.activity in response to CCCP [16]. To test whether mito-
chondrial recruitment of Parkin is sufficient for triggering
apoptotic response in the presence of valinomycin, we stably
expressed mitochondrial targeted linear ubiquitin chain
Tom70-4xUbi in Parkin2/2 MEFs along with Venus-Par-
kinC431S. Immunoblotting showed that ParkinC431S had an extra
high-molecular-weight band,whichwas independent of valino-
mycin treatment or Tom70-4xUbi expression (Figures S5A and
S5B). Upon treatment with valinomycin, Venus-ParkinC431S ac-
cumulates on mitochondria in 40% of cells expressing both
proteins, compared to less than 5% cells expressing Venus-
ParkinC431S alone at 90min (Figures S5C and S5D). Meanwhile,
valinomycin-induced apoptosis is indistinguishable between
these two cell lines, similar to the cell line expressing Venus-
ParkinS65A, whereas Venus-Parkin showed dramatic apoptotic
response (Figures S5E and S5F). Thus, in the absence of cata-
lytic activity, Parkin recruitment to mitochondria does not
switch cellular responses. This result suggests that Parkin
mitochondrial targeting alone is insufficient to trigger valinomy-
cin-induced apoptosis and is in line with the notion that Parkin
autocatalytic activation andubiquitinationofMcl-1 are required
for mediating the apoptotic responses.
Discussion
Here we show that the PINK1-Parkin pathway can mediate
different cell fates in response to different cell stress stimuli.
Weuncoveredanewproapoptotic functionofPINK1andParkin
when cells are exposed to valinomycin in addition to its
well-documented role in mitophagy and cytoprotection. The
PINK1-Parkin-dependent apoptotic response is associated
with suppression of Mcl-1. PINK1 phosphorylates Parkin at
Ser65 and unleashes the autocatalytic activity of Parkin and
ubiquitination of Mcl-1, which contributes to irreversible mole-
cular switches that result in apoptotic responses. In addition,
we reveal that PINK1 can also phosphorylate ubiquitin at
Ser65. These two posttranslational events bolster Parkin
accumulation on mitochondria and apoptotic response to
valinomycin. Our results suggest that PINK1-Parkin constitutes
a damage-gated molecular switch that governs cellular
context-specific cell fate decisions in response to variable
stress stimuli.
PINK1 as a Molecular Gauge for Cellular Stress
The antiapoptotic and cytoprotective function of PINK1
against cell stressors has been well recognized, although the
exact mechanism is still debatable. For example, PINK1 is
known to antagonize MG132-induced cell death [29–31]. The
prosurvival function of PINK1 has been attributed to the inhibi-
tion of BAX translocation by cytoplasmic PINK1 activity [31] or
phosphorylation of Bcl-xL by mitochondrial PINK1 [29, 30].
Some of the protective activity of PINK1 is independent of Par-
kin or itsmitochondria recruitment as PINK1withoutmitochon-
dria targeting signal retains antiapoptotic activity in response
to MG132 or MPTP [31, 32]. Here, we demonstrate that
PINK1 can also mediate proapoptotic signals and that this
function requires Parkin. To reconcile this apparent paradoxi-
cal role of PINK1 in cell death regulation, we have to considerion activity. Wild-type rParkin and Ser65 rParkinmutant were incubated with
n reactions. Phosphorylation of Ser65 of Parkin was monitored by a Ser65
lotting using an antibody for pSer65 Parkin, Parkin, andMcl-1. Ubiquitination
Figure 5. Phosphorylation of Parkin Ser65 Is Required for Valinomycin-Induced Apoptosis
PINK12/2 Parkin2/2 MEFhPINK1 cells expressing Venus-Parkin or mTurqoise-ParkinS65A were treated with valinomycin for the indicated times.
(A) Immunoblotting analysis of Parkin and ParkinS65A response to valinomycin treatment.
(B) Parkin mitochondrial recruitment is perturbed by Ser65 mutation. Cells expressing mTurqoise-ParkinS65A are resistance to valinomycin in apoptosis.
(C) Quantitation of (B).
(D and E) Parkin mitochondrial recruitment upon treatment with valinomycin in HeLa cells expressing either Venus-Parkin or mTurqoise-ParkinS65A (D) or
both Venus-Parkin and mTurqoise-ParkinS65A (E). Scale bars, 10 mm.
(F) Quantitation of Venus-Parkin or mTurqoise-ParkinS65A accumulation on mitochondria.
(G) Time course of Venus-Parkin and mTurqoise-ParkinS65A mitochondrial recruitment in response to valinomycin treatment in double-positive HeLa cells.
Error bars represent the SD. See also Figure S5.
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McLelland et al. recently showed that excessive production
of ROS by antimycin A causes mild oxidative damage, which
generates mitochondria-derived vesicles in PINK1- and Par-
kin-dependent manner. These vesicles contain oxidized cargothat is transported to lysosomes for disposal [24] (Figure 7).
This pathway is distinct from PINK1-Parkin-dependent mi-
tophagy, which is triggered by the dissipation of Dcm as a
result of exposure to decouplers such as CCCP and irrevers-
ible damage of mitochondria. In many cellular contexts,
Figure 6. Autocatalytic activation of Parkin by PINK1
(A) In vitro ubiquitination of wild-type and mutant Parkin through autocatalysis. A total of 0.15 mMGST-rParkin or GST-rParkinS65A was mixed with 0.45 mM
rParkinS65A prior to incubation with 0.5 mMTcPINK1 for phosphorylation at 30C for 60min. Ubiquitination reactions weremonitored by immunoblotting with
anti-Parkin or anti-pSer65 Parkin antibodies.
(B) Schematic diagram of the autocatalytic ubiquitination reaction.
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1863mitophagy or autophagy may act as a rescue mechanism that
the cell uses to escape from cell death [33]. With the treatment
of valinomycin, the severity of mitochondria or organelle dam-
age is most likely heightened to a threshold beyond repair due
to severe stress. Under these conditions, the PINK1-Parkin
pathway executes apoptotic program. Hence, the cell fate
determination dictated by PINK1 or Parkin can be stimulus
specific.
Stimuli Specific Degradation of Substrates by PINK1-
Parkin Pathway
We found that valinomycin and CCCP treatment caused
different cell fates via the same PINK1 and Parkin activation.
The levels and kinetics of Parkin mitochondrial recruitment
are comparable (Figure S1). This result suggests the cell fate
decisions are AND gates since Parkin mitochondrial recruit-
ment alone is insufficient. Indeed, we discovered that the
endogenous Mcl-1 level set by Parkin recruitment followed
by ubiquitination specifies mitophagy versus apoptosis deci-
sion in response to CCCP or valinomycin. Therefore, targeting
of Parkin to mitochondria does not lead indiscriminate sub-
strate ubiquitination. There are additional stimulus-specific
changes that are in play. Our study identified a key determi-
nant in Mcl-1 level and an AND gate in cell fate decisions.
Future studies are needed to uncover stimuli specific determi-
nant that makes Mcl-1 susceptible to Parkin ubiquitination.
Regardless of the specificity factor of Mcl-1 degradation, our
results suggest that PINK1-Parkin pathway serves as dam-
age-gated molecular switch to specify distinct cell fate deci-
sions (Figure 7).
An Autocatalytic Mechanism for the PINK1-Parkin Cascade
Mechanistically, we linked valinomycin-induced apoptotic
response to ubiquitination and degradation of Mcl-1 byParkin. Mcl-1 is an unstable protein, and its steady-state
levels are regulated by several ubiquitin E3 ligases, including
Mule [34], SCFFbw7 [35], and SCFTrCP [36]. Here, we provide
an example of a signal-regulated Mcl-1 E3 ligase in Parkin.
Using a reconstituted in vitro system, we demonstrated
that two PINK1-dependent phosphorylation events drive
amplification of its autoubiquitination and transubiquitination
activity. PINK1 directly phosphorylates Ser65 of Parkin in the
Ubl domain and ubiquitin at Ser65. This sets off an autocat-
alytic cycle for activating Parkin autoubiquitination and tran-
subiquitination of Mcl-1. While we still do not know precisely
how Ser65 phosphorylation enables Parkin to adopt an
active conformation, we can speculate that phosphorylation
in Ubl domain of Parkin may unmask the E2 docking site
[23]. It is a mystery why phosphorylated ubiquitin can pro-
mote its activity. In essence, Ser65-phosphorylated ubiquitin
could be derived from phosphorylation of autoubiquitinated
Parkin by PINK1 or conjugation of free ubiquitin phosphory-
lated by PINK1 or both. Future experiments are needed to
determine to what degree ubiquitin is phosphorylated in
cells upon PINK1 activation. We show that a Parkin mutant
defective in PINK1 phosphorylation can stimulate wild-type
Parkin E3 activity in trans. This result suggests that Parkin
is a preferred substrate for itself and that a small fraction
of Parkin phosphorylation by PINK1 can trigger nonlinear
amplification of E3 ligase activity. The positive feedback
generated by Parkin autoubiquitination and autocatalysis
is most likely an underlying mechanism for irreversible cell
fate determination. This model provides one explanation of
why wild-type Parkin can rescue the defects of Parkin
Ser65 mutant and robust Parkin accumulation on mito-
chondria. It will be interesting to determine whether this
mechanism can operate locally in a spatial constrained
manner.
Figure 7. Model Depicting the Tandem Action of PINK1-Parkin as a
Damage-Gated Molecular Switch for Cell Fate Specification
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Cell Culture, Constructs, and Antibodies
The source of cell lines, recombinant DNA constructs, and antibodies are
listed in Supplemental Experimental Procedures.
In Vitro Kinase Assay
Recombinant wild-type and D359A (kinase-dead) in the background of
MBP-TcPINK1 and the substrate His6-Sumo-Parkin (1–108) were purified,
and the kinase reactions were performed as described [11].
In Vitro Ubiquitination Assay
Purification of ubiquitin E1, E2 (UbcH7), and reagents for the in vitro ubiq-
uitination assay was described previously [37]. Wild-type or mutant Parkin
proteins were purified from Escherichia coli as described previously [23].
Human Mcl-1 (1–327 aa) was subcloned in pET15b and was purified by
Ni-NTA affinity chromatography. The ubiquitination assays were per-
formed by incubation of 1 mM His6-Mcl-1 with 0.5 mM E1, 5 mM UbcH7
(E2), 0.7 mM rParkin E3 complex, 20 mM ubiquitin (Sigma), and 1 ml 20 3
energy regeneration system (10 mM ATP, 20 mM HEPES [pH 7.4],
10 mM MgOAc, 300 mM creatine phosphate, and 0.5 mg/ml creatine phos-
phokinase) in a final volume of 20 ml. The reactions were incubated at 37C
for the indicated time, terminated by boiling in 23 SDS protein sample
buffer, and analyzed by SDS-PAGE and immunoblotting with the indicated
antibodies.
Cell Death Assays
Three independent cell death assays were used. Detailed methods of RFP-
Smac release, NucView caspase-3 biosensor, Hoechst 33258 staining, and
livecell imagingaredescribed in theSupplemental ExperimentalProcedures.
Supplemental Information
Supplemental Information includes Supplemental Experimental Proce-
dures, five figures, and threemovies and can be foundwith this article online
at http://dx.doi.org/10.1016/j.cub.2014.07.014.
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